

### 3 Novinky a trendy v léčbě glioblastomů

MUDr. Tomáš Kazda Klinika radiační onkologie LF MU, Brno, Klinika radiační onkologie MOÚ, Brno  
MUDr. Petr Pospíšil Klinika radiační onkologie LF MU, Brno, Klinika radiační onkologie MOÚ, Brno  
doc. MUDr. Radim Jančálek, Ph.D. Neurochirurgická klinika LF MU, Brno, Neurochirurgická klinika FN u sv. Anny, Brno  
MUDr. Radek Lakomý, Ph.D. Klinika komplexní onkologické péče LF MU a MOÚ, Brno  
prof. MUDr. Pavel Šlampa, CSc. Klinika radiační onkologie LF MU, Brno, Klinika radiační onkologie MOÚ, Brno

### 3 Mechanismy patologické imunoregulace u nádorů, zprostředkované PD-1 a jeho ligandem PD-L1

MUDr. Eugen Kubala Klinika onkologie a radioterapie FN, Hradec Králové

### 4 Karcinom plic

prof. MUDr. Jana Skříčková, CSc. | MUDr. Ondřej Venclíček | MUDr. Bohdan Kadlec |  
MUDr. Marcela Tomišková | MUDr. Lenka Jakubíková | MUDr. Jana Špaldová  
Klinika nemocí plicních a tuberkulózy LF Masarykovy univerzity a FN, Brno

### 5 Imunoterapie u nemalobuněčného plicního karcinomu

doc. MUDr. Milada Zemanová, Ph.D. Onkologická klinika 1. LF UK a VFN, Praha

### 5 Erlotinib + bevacizumab v první linii léčby nemalobuněčného karcinomu plic u nemocných s mutacemi EGFR

MUDr. Juraj Kultán | MUDr. Ivona Grygárková, Ph.D. | prof. MUDr. Vítězslav Kolek, DrSc.  
Klinika plicních nemocí a tuberkulózy, FN a LF UP, Olomouc

### 6 Testování PD-L1 – nová výzva v prediktivní diagnostice nemalobuněčných plicních karcinomů

prof. MUDr. Aleš Ryška, Ph.D. | MUDr. Markéta Nová | MUDr. Tomáš Rozkoš |  
MUDr. Helena Hornychová, Ph.D. Fingerlandův ústav patologie LF UK a FN, Hradec Králové

### 6 Kombinace chemoterapie a ADT u naivních nemocných s karcinomem prostaty

prof. MUDr. Jindřich Fínek, Ph.D., MHA Onkologická a radioterapeutická klinika FN a LF UK, Plzeň

### 6 Optimální sekvence léčby nemocných s metastatickým kastračně rezistentním prostatickým karcinomem

prof. MUDr. Jindřich Fínek, Ph.D., MHA Onkologická a radioterapeutická klinika FN a LF UK, Plzeň

### 7 Terapie karcinomu prsu ve světle nejnovějších poznatků – zaměřeno na systémovou terapii

MUDr. Markéta Palácová Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno

### 7 Možnosti léčby pokročilého karcinomu prsu při výskytu hormonální rezistence

MUDr. Zdeněk Linke Onkologická klinika FN Motol, Praha

### 8 Lipegfilgrastim v prevenci febrilní neutropenie ve studii z klinické praxe NADIR

prof. MUDr. Jindřich Fínek, Ph.D., MHA Onkologická a radioterapeutická klinika FN a LF UK, Plzeň

### 8 Kudy v léčbě metastatického maligního melanomu

MUDr. Ivana Krajsová, MBA Dermatovenerologická klinika VFN a 1. LF UK

### 8 Melanom v roce 2016: diagnostika a možnosti léčby

Rozhovor Dany Frantálové s Petrem Arenbergerem, Ivanou Krajsovou a Radkem Lakomým

### 9 Sarkomy měkkých tkání – vzácné tumory s nutností léčby v centrech

MUDr. Kateřina Kopečková Onkologická klinika 2. LF UK, FN Motol, Praha  
RNDr. Lenka Krsková, Ph.D. Ústav patologie a molekulární medicíny 2. LF UK a FN Motol, Praha

### 9 Cílená léčba karcinomu ovaria – současnost a novinky

doc. MUDr. Michal Zikán, Ph.D. Onkogynekologické centrum, Gynekologicko-porodnická klinika 1. LF UK a VFN, Praha

### 9 ESMO 2016: léčba metastatického kolorektálního karcinomu

MUDr. Jiří Tomášek, Ph.D. Klinika komplexní onkologické péče MOÚ, Brno

### 10 Novinky v systémové léčbě pokročilého karcinomu ledvin

MUDr. Kateřina Kopečková Onkologická klinika, II. LF UK a FN Motol, Praha

- 10 Fixní kombinace oxykodon/naloxon v léčbě kombinované bolesti – klinická kazuistika**  
doc. MUDr. Luboš Holubec, Ph.D. Biomedicínské centrum, LF v Plzni, UK Praha, Oddělení klinické onkologie, Nemocnice Na Homolce, Praha  
MUDr. Lenka Lisnerová | MUDr. Martin Šalanda Oddělení klinické onkologie, Nemocnice Na Homolce, Praha  
MUDr. Václav Liška, Ph.D. Biomedicínské centrum, LF v Plzni, UK Praha
- 10 ASCO 2016: Avastin ve světle novinek**  
MUDr. Tomáš Svoboda, Ph.D. Komplexní onkologické centrum FN, Plzeň
- 11 Pokroky v systémové léčbě karcinomu děložního hrdla**  
MUDr. Igor Sirák, Ph.D. Klinika onkologie a radioterapie FN, Hradec Králové
- 11 Proč k fentanylovým náplastem přidávat i Effentoru? Zkušenosti z oddělení**  
MUDr. Josef Kvěch Radioterapeuticko-onkologické oddělení FN Motol, Praha
- 11 Nádory gastrointestinálního traktu, dopad na nutriční stav pacientů a možnosti nutriční podpory**  
MUDr. Petra Holečková, Ph.D., MBA Ústav radiační onkologie, Nemocnice Na Bulovce a 1. LF UK, Praha
- 11 Imunoglobuliny v sekundární imunodeficienci**  
MUDr. Mgr. Jitka Petanová, CSc. Ústav imunologie a mikrobiologie, 1. LF UK a VFN, Praha

# Novinky a trendy v léčbě glioblastomů

MUDr. Tomáš Kazda Klinika radiační onkologie LF MU, Brno, Klinika radiační onkologie MOÚ, Brno

MUDr. Petr Pospíšil Klinika radiační onkologie LF MU, Brno, Klinika radiační onkologie MOÚ, Brno

doc. MUDr. Radim Jančálek, Ph.D. Neurochirurgická klinika LF MU, Brno,

Neurochirurgická klinika FN u sv. Anny, Brno

MUDr. Radek Lakomý, Ph.D. Klinika komplexní onkologické péče LF MU a MOÚ, Brno

prof. MUDr. Pavel Šlampa, CSc. Klinika radiační onkologie LF MU, Brno,

Klinika radiační onkologie MOÚ, Brno

- Adeberg, S. – Bostel, T. – Harrabi, S., et al.: Impact of delays in initiating postoperative chemoradiation while determining the MGMT promoter-methylation statuses of patients with primary glioblastoma. *BMC Cancer*, 2015, 15, 558.
- Dusek, L. – Muzik, J. – Maluskova, D., et al.: Cancer incidence and mortality in the Czech Republic. *Klin Onkol*, 2014, 27, s. 406–423.
- Ellingson, B. M. – Bendszus, M. – Boxerman, J., et al.: Jumpstarting Brain Tumor Drug Development Coalition Imaging Standardization Steering Committee. Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. *Neuro Oncol*, 2015, 17, s. 1188–1198.
- Friedman, H. S. – Prados, M. D. – Wen, P. Y., et al.: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. *J Clin Oncol*, 2009, 27, s. 4733–4740.
- Gilbert, M. R. – Digram, J. J. – Armstrong, T. S., et al.: A randomized trial of bevacizumab for newly diagnosed glioblastoma. *N Engl J Med*, 2014, 370, s. 699–708.
- Hegi, M. E. – Diserens, A. C., et al.: MGMT gene silencing and benefit from temozolomide in glioblastoma. *N Engl J Med*, 2005, 352, s. 997–1003.
- Chowdhary, S. A. – Ryken, T. – Newton, H. B.: Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis. *J Neurooncol*, 2015, 122, s. 367–382.
- Chinot, O. L. – Wick, W. – Mason, W., et al.: Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. *N Engl J Med*, 2014, 370, s. 709–722.
- Chinot, O. L. – Nishikawa, R. – Mason, W., et al.: Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio. *Neuro Oncol*, 22. 3. 2016, pii: now046, Epub před tiskem.
- Kazda, T. – Bulik, M. – Pospíšil, P., et al.: Advanced MR increases the diagnostic accuracy of recurrent glioblastoma: Single institution thresholds and validation of MR spectroscopy and diffusion weighted MR paging. *NeuroImage: Clinical*, 2016, 11, s. 316–321.
- Kreisl, T. N. – Kim, L. – Moore, K., et al.: Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. *J Clin Oncol*, 2009, 27, s. 740–745.
- Lacroix, M. – Abi-Said, D. – Fournier, D. R., et al.: A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. *J Neurosurg*, 2001, 95, s. 190–198.
- Lakomý, R. – Fadrus, P. – Slampa, P., et al.: Multimodal treatment of glioblastoma multiforme: results of 86 consecutive patients diagnosed in period 2003–2009. *Klin Onkol*, 2011, 24, s. 112–120.
- Lattermann, A. – Baumann, M. – Krause, M.: Clinical trials for personalized glioblastoma radiotherapy: Markers for efficacy and late toxicity but often delayed treatment – Does that matter? *Radiother Oncol*, 2016, 118, s. 211–213.
- Liang, T. H. – Kuo, S. H. – Wang, C. W., et al.: Adverse prognosis and distinct progression patterns after concurrent chemoradiotherapy for glioblastoma with synchronous subventricular zone and corpus callosum invasion. *Radiother Oncol*, 2016, 118, s. 16–23.
- Loureiro, L. V., et al.: Minimizing the uncertainties regarding the effects of delaying radiotherapy for Glioblastoma: A systematic review and meta-analysis. *Radiother Oncol*, 2016, 118, s. 1–8.
- Malmström, A. – Grönberg, B. H. – Marosi, C., et al.: Nordic Clinical Brain Tumour Study Group (NCBTS). Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. *Lancet Oncol*, 2012, 13, s. 916–926.
- Niyazi, M. – Brada, M. – Chalmers, A. J., et al.: ESTRO-ACROP guideline “target delineation of glioblastomas”. *Radiother Oncol*, 2016, 118, s. 35–42.
- Okada, H. – Keller, M. – Juany, R., et al.: Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. *Lancet Oncol*, 2015, 16, s. e534–e542.
- Petr, J. – Platzeck, I. – Seidlitz, A., et al.: Early and late effects of radiochemotherapy on cerebral blood flow in glioblastoma patients measured with non-invasive perfusion MR. *Radiother Oncol*, 2016, 118, s. 24–28.
- Preusser, M. – Lim, M. – Hafner, D. A., et al.: Prospects of immune checkpoint modulators in the treatment of glioblastoma. *Nat Rev Neuro*, 2015, 11, s. 504–514.
- Sandmann, T. – Bourgon, R. – Garcia, J., et al.: Patients with proneural glioblastoma may derive overall survival benefit from the addition of bevacizumab to first-line radiotherapy and temozolomide: Retrospective analysis of the AVAglio Trial. *J Clin Oncol*, 2015, 33, s. 2735–2744.
- Schumacher, D. – Hackenberger, C. P. – Leonhardt, H., et al.: Current status: Site-specific antibody drug conjugates. *J Clin Immunol*, 22. 3. 2016, Epub před tiskem.
- Stupp, R. – Mason, W. P. – van den Bent, M. J., et al.: and the European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups and the National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N Engl J Med*, 2005, 352, s. 987–996.
- Stupp, R. – Hegi, M. E. – Mason, W. P., et al.: and the European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. *Lancet Oncol*, 2009, 10, s. 459–466.
- Stupp, R. – Brada, M. – van den Bent, M. J., et al.: ESMO Guidelines Working Group. High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*, 2014, 25, dopl. 3, s. iii93–iii101.
- Stupp, R. – Taillibert, S. – Banner, A. A., et al.: Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: A randomized clinical trial. *JAMA*, 2015, 314, s. 2535–2543.
- Swanson, K. D. – Lok, E. – Wong, E. T.: An overview of alternating electric fields therapy (NovoTTF Therapy) for the treatment of malignant glioma. *Curr Neurol Neurosci Rep*, 2016, 16, s. 8.
- Valtonen, S. – Timonen, U. – Toivanen, P., et al.: Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. *Neurosurgery*, 1997, 41, s. 44–48, diskuze s. 48–49.
- Van Meir, E. G. – Hadjipanayis, C. G. – Norden, A. D., et al.: Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. *CA Cancer J Clin*, 2010, 60, s. 166–193.
- Verhaak, R. G. – Hoadley, K. A. – Purdom, E., et al.: Cancer Genome Atlas Research Network. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. *Cancer Cell*, 2010, 17, s. 98–110.
- Waitkus, M. S. – Diplas, B. H. – Yan, H.: Isocitrate dehydrogenase mutations in gliomas. *Neuro Oncol*, 2016, 18, s. 16–26.
- Keller, M. – Pfister, S. M. – Wick, W., et al.: Molecular neuro-oncology in clinical practice: a new horizon. *Lancet Oncol*, 2013, 14, s. e370–e379.
- Wen, P. Y. – MacDonald, D. R. – Reardon, D. A., et al.: Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. *J Clin Oncol*, 2010, 28, s. 1963–1972.
- Whitfield, G. A. – Kennedy, S. R. – Djoukadar, I. K. – Jackson, A.: Imaging and target volume delineation in glioma. *Clin Oncol (R Coll Radiol)*, 2014, 26, s. 364–376.
- Wick, W. – Platten, M. – Meisner, C., et al.: NOA-08 Study Group of Neuro-oncology Working Group (NOA) of German Cancer Society. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. *Lancet Oncol*, 2012, 13, s. 707–715.
- Wick, W.: TTF fields: where does all the skepticism come from? *Neuro Oncol*, 2016, 18, s. 303–305.
- Wick, W. – Platten, M. – Wick, A., et al.: Current status and future directions of anti-angiogenic therapy for gliomas. *Neuro Oncol*, 2016, 18, s. 315–328.

## Mechanismy patologickej imunoregulace u nádorů, zprostředkované PD-1 a jeho ligandem PD-L1

MUDr. Eugen Kubala Klinika onkologie a radioterapie FN, Hradec Králové

- Topalian, S. L. – Werner, G. – Pardoll, D. M.: Cancer immunotherapy comes of age. *J Clin Oncol*, 2011, 29, s. 4828–4836.
- Shinohara, T. – Taniwaki, M. – Ishida, Y., et al.: Structure and chromosomal localization of the human PD-1 gene (PDCD1). *Genomics*, 23, 1994, s. 704–706.
- PDCD1 programmed cell death 1 [Homo sapiens (human)]. Gene ID: 5133, aktualizováno 19. 7. 2016, dostupné z: <http://www.ncbi.nlm.nih.gov/gene/5133>, vyhledáno 28. 7. 2016.
- Francisco, L. M. – Sage, P. T. – Sharp, A. H.: The PD-1 pathway in tolerance and autoimmunity. *Immunol Rev*, 2010, 236, s. 219–242.
- Fife, B. T. – Paulem, K. E.: The role of the PD-1 pathway in autoimmunity and peripheral tolerance. *An NY Acad Sci*, 2011, 1217, s. 45–59.
- Ishida, Y. – Agata, Y. – Shibahara, K.: Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. *EMBO J*, 1992, 11, s. 3887–3895.
- Nishimura, H. – Nose, M. – Hiai, H.: Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. *Immunity*, 1999, 11, s. 141–151.
- Nishimura, H. – Okazaki, T. – Tahara, Y., et al.: Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. *Science*, 2001, 291, s. 319–322.
- Latchman, Y. – Wood, C. R. – Chernova, T., et al.: PD-L1 is a second ligand for PD-1 and inhibits T cell activation. *Nat Immunol*, 2001, 2, s. 261–268.
- Keir, M. E. – Butte, M. J. – Freeman, G. J., et al.: PD-1 and its ligands in tolerance and immunity. *An Rev Immunol*, 2008, 26, s. 677–704.
- Ghiotto, M. – Gauthier, L. – Serriari, N., et al.: PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1. *Int Immunol*, 2010, 22, s. 651–660.
- Hiaroka, N.: Tumor-infiltrating lymphocytes and hepatocellular

- carcinoma: molecular biology. *Int J Clin Oncol*, 2010, 15, s. 544–551.
- 13 Ramsay, A. G.: Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity. *Br J Haematol*, 2013, 162, s. 313–325.
  - 14 Pardoll, D. M.: The blockade of immune checkpoints in cancer immunotherapy. *Nat Rev Cancer*, 2012, 12, s. 252–264.
  - 15 Barber, D. L. – Sherry, E. J., et al.: Restoring function in exhausted CD8 T cells during chronic viral infection. *Nature*, 2006, 439, s. 682–687.
  - 16 Dong, H., et al.: Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. *Nat Med*, 2002, 8, s. 793–800.
  - 17 Petroff, M. G. – Chen, L. – Philips, T. A., et al.: B7 family molecules: novel immunomodulators at the maternal-fetal interface. *Placenta*, 2002, 23, s. S95–S101.
  - 18 Hirano, F., et al.: Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. *Cancer Res*, 2005, 65, s. 1089–1096.
  - 19 Chen, L.: Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. *Nat Rev Immunol*, 2004, 4, s. 336–347.
  - 20 Dong, H. – Zhu, G. – Tamada, K., et al.: B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. *Nat Med*, 1999, 5, s. 1365–1369.
  - 21 Selenko-Gebauer, N. – Majdic, O. – Szekeres, A., et al.: B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell energy. *J Immunol*, 2003, 170, s. 3637–3644.
  - 22 Tsushima, F., et al.: Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell energy. *Blood*, 2007, 110, s. 180–185.
  - 23 Goldberg, M. V., et al.: Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. *Blood*, 2007, 110, s. 186–192.
  - 24 Barber, D. L., et al.: Restoring function in exhausted CD8 T cells during chronic viral infection. *Nature*, 2006, 439, s. 682–687.
  - 25 Francisco, L. M., et al.: PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. *J Exp Med*, 2009, 206, s. 3015–3029.
  - 26 Amarnath, S., et al.: The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. *Sci Transl Med*, 2011, 3, s. 111–120.
  - 27 Yao, S., et al.: PD-1 on dendritic cells impedes innate immunity against bacterial infection. *Blood*, 2009, 113, s. 5811–5818.
  - 28 Azuma, T. – Yao, S. – Zhu, G., et al.: B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. *Blood*, 2008, 111, s. 3635–3643.
  - 29 Zou, W. – Chen, L.: Inhibitory B7-family molecules in the tumour microenvironment. *Nat Rev Immunol*, 2008, 8, s. 467–477.
  - 30 Flies, D. B. – Sander, B. J. – Szno, M., et al.: Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy. *Yale J Biol Med*, 2011, 84, s. 409–421.
  - 31 Taube, J. M., et al.: Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. *Sci Transl Med*, 2012, 4, s. 127–137.
  - 32 Boehm, U. – Klamp, T. – Groot, M., et al.: Cellular responses to interferon-gamma. *An Rev Immunol*, 1997, 15, s. 749–795.
  - 33 Schroder, K. – Hertzog, P. J. – Kavasi, T., et al.: Interferon-gamma: an overview of signals, mechanisms and functions. *J Leukoc Biol*, 2004, 75, s. 163–189.
  - 34 Spranger, S., et al.: Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. *Sci Transl Med*, 2013, 5, s. 200ra116.
  - 35 Velcheti, V., et al.: Programmed death ligand-1 expression in non-small cell lung cancer. *Lab Invest*, 2014, 94, s. 107–116.
  - 36 Parsa, A. T., et al.: Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. *Nat Med*, 2007, 13, s. 84–88.
  - 37 Akbay, E. A., et al.: Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. *Cancer Discov*, 2013, 3, s. 1355–1363.
  - 38 Marzec, M., et al.: Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). *Proc Natl Acad Sci U S A*, 2008, 105, s. 20852–20857.
  - 39 Rosenberg, S. A., et al.: Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. *J Immunol*, 2005, 175, s. 6169–6176.
  - 40 Rosenberg, S. A. – Yang, J. C. – Restifo, N. P.: Cancer immunotherapy: moving beyond current vaccines. *Nat Med*, 2004, 10, s. 909–915.
  - 41 Schwartzentruber, D. J. – Lawson, D. H. – Richards, J. M., et al.: gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. *N Engl J Med*, 2011, 364, s. 2119–2127.
  - 42 Zou, W.: Immunosuppressive networks in the tumor environment and their therapeutic relevance. *Nat Rev Cancer*, 2005, 5, s. 263–274.
  - 43 Szno, M. – Chen, L.: Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. *Clin Cancer Res*, 2013, 19, s. 1021–1034.
  - 44 Galon, J. – Angell, H. K. – Bedognetti, D., et al.: The continuum of cancer immunosurveillance: Prognostic, predictive, and mechanistic signatures. *Immunity*, 2013, 39, s. 11–26.
  - 45 Chen, L. – Han, X.: Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. *J Clin Invest*, 2015, 125, s. 3384–3391.

## Karcinom plic

prof. MUDr. Jana Skříčková, CSc. | MUDr. Ondřej Venclíček | MUDr. Bohdan Kadlec |  
MUDr. Marcela Tomíšková | MUDr. Lenka Jakubíková | MUDr. Jana Špaldová  
Klinika nemocí plicních a tuberkulózy LF Masarykovy univerzity a FN, Brno

- 1 Siegel, R., et al.: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. *CA Cancer J Clin*, 2011, 61, s. 212–236.
- 2 Howlader, N., et al., editors: *SEER Cancer Statistics Review, 1975–2008*. National Cancer Institute, 2010, dostupné z: [http://seer.cancer.gov/csr/1975\\_2008/](http://seer.cancer.gov/csr/1975_2008/), vyhledáno 22. 6. 2016.
- 3 www.svod.cz
- 4 Skříčková, J. – Koleč, V. – Pešek, M. – Melichar, B. – Petruželka, L. – Büchler, T. – Burger, M. – Hejduk, K. – Klíka, P. – Jarkovský, J. – Dušek, L.: Mapování epidemiologické situace nemalobuněčného karcinomu plic a obraz léčebné péče v ČR s důrazem na léčbu neresekovatelného a metastatického stadia v letech 2007–2013. *Ekonomie ve zdravotnictví & hodnocení zdravotnických technologií*, 2016, 2, s. 24–32.
- 5 Pavlík, T., et al.: Trends in stage-specific population-based survival of cancer patients in the Czech Republic in the period 2000–2008. *Cancer Epidemiology*, 2013, DOI: 10.1016/j.canep.2013.11.002.
- 6 Francisci, S., et al.: Survival patterns in lung and pleural cancer in Europe 1999–2007: Results from the EURO-CARE-5 study. *European Journal of Cancer*, 2015, 51, s. 2099–2268.
- 7 Laskin, J. J. – Sander, A. B.: State of the art in therapy for non-small cell lung cancer. *Cancer Invest*, 2005, 23, s. 427–442.
- 8 Travis, W. D. – Brambilla, E. – Noguchi, M., et al.: International association for the study of lung cancer / American Thoracic Society / European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. *J Thorac Oncol*, 2011, 6, s. 244–285.
- 9 Pešek, M.: Nemalobuněčný karcinom plic. EUNI, dostupné z: <http://www.euni.cz/tema.php>, vyhledáno 22. 6. 2016.
- 10 Paz-Ares, L. – de Marinis, F., et al.: Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. *Lancet Oncol*, 2012, 13, s. 247–255.
- 11 Lynch, T. J. – Bell, D. W. – Sordella, R., et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med*, 2004, 350, s. 2129–2139.
- 12 Duffield, E. L. – Watkins, C. L. – Armour, A. A. – Fukuoka, M.: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N Engl J Med*, 2009, 361, s. 947–957.
- 13 Douillard, J. – Ostoros, G. – Cobo, M., et al.: Efficacy, safety and tolerability results from a phase IV, open-label, single arm study of 1st-line gefitinib in Caucasian patients (PTS) with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). *Lung Cancer*, 2013, 80, s. S31.
- 14 Skříčková, J. – Bortlíček, Z. – Hejduk, K., et al.: Gefitinib in front line treatment of patients with NSCLC in the Czech Republic: Analysis of 113 patients. *European Respiratory Journal Munich*, 2014, 44, 1–1, online.
- 15 Rosell, R. – Carcereny, E. – Gervais, R., et al.: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EUR-TAC): a multicentre, open-label, randomised phase 3 trial. *Lancet Oncol*, 2012, 13, s. 239–246.
- 16 Shepherd, F. A. – Pereira, J. R. – Ciuleanu, T., et al.: Erlotinib in previously treated non-small-cell lung cancer. *N Engl J Med*, 2005, 353, s. 123–132.
- 17 Yang, J. Ch. – Schuler, M. – Yamamoto, N., et al.: LUX-Lung 3: a randomized, open-label, Phase III study of afatinib vs cisplatin/pemetrexed as 1st-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. *J Clin Oncol*, 2012, 30, abstrakt LBA7500.
- 18 Wu, Y.: LUX-Lung 6: A randomized, open-label, Phase III study of afatinib (A) vs. gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung. American Society of Clinical Oncology, Chicago, 2. 6. 2013. *J Clin Oncol*, 2013, 31, abstrakt 8016.
- 19 Yang, J. Ch. – Sequist, L. V. – Schuler, M., et al.: Overall survival in patients with advanced NSCLC harboring common (Del19/L858R) EGFR mutations: analysis of two large, open-label phase III studies of afatinib vs chemotherapy, LUX-Lung 3 and LUX-Lung 6. ASCO 2014.
- 20 Park, K. – Tan, E. – Zhaní, L., et al.: Afatinib (A) vs gefitinib (G) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring activating EGFR mutations: results of the global, randomized, open-label, Phase IIb trial LUX-Lung 7 (LL7). ESMO Asia 2015, abstrakt LBA2\_PR, dostupné z: <https://slides.ctimeeting-tech.com/library/esmo/browse/itinerary/5225/2015-12-20#2y6N0cj>, vyhledáno 18. 1. 2016.
- 21 Data FDA, dostupné z: <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm472525.htm>, vyhledáno 22. 6. 2016.
- 22 Data EMA, dostupné z: [http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004124/human\\_med\\_001961.jsp&mid=WC0b01ac0580001d124](http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004124/human_med_001961.jsp&mid=WC0b01ac0580001d124), vyhledáno 22. 6. 2016.
- 23 Gross, D. A. E., et al.: AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. *Cancer Discovery*, 2014, 4, s. 1046–1061.
- 24 Data AstraZeneca, dostupné z: <https://www.astrazeneca.com/media-centre/press-releases/2016/tagrisso-osimertinib-approved-in-eu-as-first-in-class-treatment-for-lung-cancer-03022016.html>, vyhledáno 22. 6. 2016.
- 25 Soda, M. – Choi, Y. L. – Enomoto, M., et al.: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. *Nature*, 2007, 448, s. 561–566.
- 26 Wong, D. W. – Leung, E. L. – So, K. K., et al.: The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. *Cancer*, 2009, 115, s. 1723–1733.
- 27 Shaw, A. T. – Salomon, B.: Targeting anaplastic lymphoma kinase in lung cancer. *Clin Cancer Res*, 2011, 17, s. 2081–2086.
- 28 Takeuchi, K. – Choi, Y. L. – Togashi, Y., et al.: KIF5B-ALK, a novel fusion oncokinasé definovaná by imunohistochemií based diagnostic system for ALK-positive lung cancer. *Clin Cancer Res*, 2009, 15, s. 3143–3149.
- 29 Shaw, A. T. – Trap, B. Y. – Salomon, B. J., et al.: Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. *Lancet Oncol*, 2011, 12, s. 1004–1012.
- 30 Shaw, A. T. – Kim, D. W. – Mehra, R., et al.: Ceritinib in ALK-rearranged non-small-cell lung cancer. *N Engl J Med*, 2014, 370, s. 1189–1197, DOI: 10.1056/NEJMoa1311107.
- 31 Reck, M. – von Pawel, J. – Zatloukal, P., et al.: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAIL. *J Clin Oncol*, 2009, 27, s. 2415.
- 32 Reck, M.: Nintedanib (BIBF 1120) plus docetaxel in NSCLC patients progressing after first-line chemotherapy: LUME Lung 1, a randomized, double-blind phase III trial. 2013 ASCO Annual Meeting. *J Clin Oncol*, 2013, 31, abstrakt LBA8011.
- 33 Hanna, N.: LUME-Lung 2: A multicentre, randomized, double-blind, Phase III study of nintedanib plus pemetrexed vs. placebo plus pemetrexed in patients with advanced non-squamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy. American Society of Clinical Oncology, Chicago, 2. 6. 2013. *J Clin Oncol*, 2013, 31 abstrakt 8034.
- 34 Thatcher, N. – Hirsch, F. R. – Szczesna, A., et al.: A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC). *J Clin Oncol*, 2014, 32, abstrakt 8008.
- 35 Perol, M. – Ciuleanu, T. E. – Arrieta, O., et al.: REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy. *J Clin*

- Oncol*, 2014, 32, abstrakt LBA8006.
- 36 Koubková, L.: Imunoterapie karcinomu plic. *Postgraduální medicína*, 2015, 17, s. 51–54.
  - 37 Spigel, D. L., et al.: A phase III study (CheckMate 017) of nivolumab (NIVO); anti-programmed death-1 (PD-1) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC). *J Clin Oncol*, 2015, 33, abstrakt 8009.
  - 38 Paz-Ares, L., Horn, L., Borghaei, H., et al.: Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). *J Clin Oncol*, 2015, 33, abstrakt LBA109.
  - 39 Garon, E. B., Rizvi, N. A., Hui, R., et al.: KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small-cell lung cancer. *N Engl J Med*, 2015, 372, s. 2018–2028, doi: 10.1056/NEJMoa1501824, Epub 19. 4. 2015.
  - 40 Herbst, R. S., Kim, D. W., Felip, E., et al.: KEYNOTE-010: Phase 2/3 study of pembrolizumab (MK-3475) vs docetaxel for PD-L1-positive NSCLC after platinum-based therapy. Prezentováno na: ESMO Asia 2015 Congress, Singapur, 18.–21. 12. 2015, LBA3 PR.
  - 41 Vallieres, E., Shepherd, F. A., Crowley, J., et al.: The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forth coming (seventh) edition of the TNM classification for lung cancer. *J Thorac Oncol*, 2009, 4, s. 1049–1059.
  - 42 Almquist, D., Mosalpuria, K., Ganti, A. K.: Multimodality therapy for limited-stage small-cell lung cancer. *J Oncol Practice*, 2016, 12, s. 111–117.
  - 42 Corso, Ch. D., Rutter, Ch. E., Park, H. S., et al.: Role of chemoradiotherapy in elderly patients with limited-stage small-cell lung cancer. *J Clin Oncol*, 2015, 33, s. 4240–4246.
  - 43 NCCN Clinical Practice Guidelines in Oncology: Small cell lung cancer. NCCN National Comprehensive Cancer Network, verze 1. 2008, 2007, www.nccn.org, s. 24–25.
  - 44 Niho, S., Kubota, K., Yoh, K., et al.: Clinical outcome of chemoradiotherapy in patients with limited-disease small cell lung cancer with ipsilateral pleural effusion. *J Thorac Oncol*, 2008, 3, s. 723–727.
  - 45 Patel, S., MacDonald, O. K., Suntharalingam, M.: Evaluation of the use of prophylactic cranial irradiation in small cell lung cancer. *Cancer*, 2009, 115, s. 842–850.
  - 46 Hanna, N., Bunn, P. A., Langer, C., et al.: Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. *J Clin Oncol*, 2006, 24, s. 2038–2043.
  - 47 Schneider, B. J.: Management of recurrent small cell lung cancer. *J Natl Compr Canc Netw*, 2008, 6, s. 323–331.
  - 48 Nawal, L., Islam, K. M. M., Devyani, P. E., et al.: Survival trends of small cell lung cancer (SCLC) in the United States: A SEER database analysis. *J Thorac Oncol*, 2015, 10, s. S402.
  - 49 Karavasili, V., Kotsakis, A., Agelakis, S., et al.: Pazopanib as second line treatment of platinum sensitive SCLC patients: a multicenter phase II trial of the Hellenic Oncology Research Group. *J Thorac Oncol*, 2015, 10, s. S401.
  - 50 Tagrisso Assessment report ze dne 17. 12. 2015, dostupné z: [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/EPAR\\_-\\_Public\\_assessment\\_report/human/004124/WC500202024.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004124/WC500202024.pdf), vyhledáno 24. 6. 2016.
  - 51 Brahmer, J., Reckamp, K. L., Baas, P., et al.: Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. *N Engl J Med*, 2015, 373, s. 123–135.

## Imunoterapie u nemalobuněčného plicního karcinomu

doc. MUDr. Milada Zemanová, Ph.D. Onkologická klinika 1. LF UK a VFN, Praha

- 1 ÚZIS ČR, NOR ČR 2011: *Novotvary 2011, Cancer Incidence 2011 in the Czech Republic*.
- 2 Peters, S., Adjei, A. A., Gridelli, C., et al.: Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*, 2012, 23, dopl. 7, s. vii56–64.
- 3 Mok, T. S.: Personalized medicine in lung cancer: what we need to know. *Nat Rev Clin Oncol*, 2011, 8, s. 661–668.
- 4 Cataldo, V. D., Gibbons, D. L., Pérez-Soler, R., et al.: Treatment of non-small-cell lung cancer with erlotinib or gefitinib. *N Engl J Med*, 2011, 364, s. 947–955.
- 5 Klak, E. L., Bang, Y. J., Camidge, D. R., et al.: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. *N Engl J Med*, 2010, 363, s. 1693–1703.
- 6 Aerts, J. G., Lievense, L. A., Hoogsteden, H. C., et al.: Immunotherapy prospects in the treatment of lung cancer and mesothelioma. *Hegmans Transl Lung Cancer Res*, 2014, 3, s. 34–45.
- 7 Pirker, R., Pereira, J. R., von Pawel, J., et al.: EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. *Lancet Oncol*, 2012, 13, s. 33–42.
- 8 Sandler, A., Gray, R., Perry, M. C., et al.: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. *N Engl J Med*, 2006, 355, s. 2542–2550.
- 9 Lynch, T. J., Bondarenko, I., et al.: Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. *J Clin Oncol*, 2012, 30, s. 2046–2054.
- 10 Brahmer, J., Reckamp, K. L., Baas, P., et al.: Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. *N Engl J Med*, 2015, 373, s. 123–135.
- 11 Paz-Ares, L., Horn, L., Borghaei, H., et al.: Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). *J Clin Oncol*, 2015, 33, dopl., abstrakt LBA109.
- 12 Garon, E. B., Rizvi, N. A., Hui, R., et al.: KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small-cell lung cancer. *N Engl J Med*, 2015, 372, s. 2018–2028.
- 13 Spigel, D. R., Socinski, M. A.: Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches. *J Thorac Oncol*, 2013, 8, s. 587–598.
- 14 Yang, L., Wang, L., Zhang, Y.: Immunotherapy for lung cancer: advances and prospects. *Am J Clin Exp Immunol*, 2016, 5, s. 1–20.
- 15 Vansteenkiste, J. F., Cho, B. C., Vanakesa, T., et al.: Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol*, 2016, 17, s. 2016.
- 16 Butts, C., Socinski, M. A., Mitchell, P. L., et al.: START trial team. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. *Lancet Oncol*, 2014, 15, s. 59–68.
- 17 Ramlogan-Steel, C. R., Steel, J. C., Morris, J. C.: Lung cancer vaccines: current status and future prospects. *Transl Lung Cancer Res*, 2014, 3, s. 46–52.
- 18 Fernández, L. A., Acosta, B. S., Neningen, V. E., et al.: Effect of blockade of the EGF system on wound healing in patients vaccinated with CIMAvax® EGF. *World J Surg Oncol*, 2013, 11, s. 275.
- 19 Georgoulas, V., Douillard, J. Y., Khayat, D., et al.: A multicenter randomized phase IIb efficacy study of Vx-001, a peptide-based cancer vaccine as maintenance treatment in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics. *Clin Lung Cancer*, 2013, 14, s. 461–465.
- 20 Zhang, L., Yang, X., Sun, Z., et al.: Dendritic cell vaccine and cytokine-induced killer cell therapy for the treatment of advanced non-small cell lung cancer. *Oncol Lett*, 2016, 11, s. 2605–2610, Epub 24. 2. 2016.
- 21 Podrazil, M., Horváth, R., Becht, E., et al.: Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCA) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer. *Oncotarget*, 2015, 6, s. 18192–18205.
- 22 Domagala-Kulawik, J.: The role of the immune system in non-small cell lung carcinoma and potential for therapeutic intervention. *Transl Lung Cancer Res*, 2015, 4, s. 177–190.

## Erlotinib + bevacizumab v první linii léčby nemalobuněčného karcinomu plic u nemocných s mutacemi EGFR

MUDr. Juraj Kultán | MUDr. Ivona Grygárková, Ph.D. | prof. MUDr. Vítězslav Kolek, DrSc.

Klinika plicních nemocí a tuberkulózy, FN a LF UP, Olomouc

- 1 <http://www.cancerresearchuk.org/cancerstats/world>, vyhledáno 27. 8. 2016.
- 2 [http://globocan.iarc.fr/Pages/summary\\_table\\_site\\_sel.aspx](http://globocan.iarc.fr/Pages/summary_table_site_sel.aspx), vyhledáno 27. 8. 2016.
- 3 <http://www.uzis.cz/publikace/tuberkuloza-respiracni-nemoci>, vyhledáno 23. 9. 2016.
- 4 National Cancer Institute, Surveillance, Epidemiology, and End Results Program, vyhledáno 20. 7. 2016, dostupné z: <http://seer.cancer.gov/statfacts/html/lungb.html>.
- 5 Kondo, I., Shimizu, N.: Mapping of the human gene for epidermal growth factor receptor (EGFR) on the p13-q22 region of chromosome 7. *Cytogenet Cell Genet*, 1983, 35, s. 9–14.
- 6 Hirsch, F. R., Herbst, R. S., Olsen, C., et al.: Increased EGFR gene copy number detected by fluorescent in situ hybridizations predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. *Clin Oncol*, 2008, 26, s. 3351–3357.
- 7 Zhang, Z., Stiegler, A. L., Boggo, T. J., et al.: EGFR-mutated lung cancer: a paradigm of molecular oncology. *Oncotarget*, 2010, 1, s. 497–514.
- 8 Sequist, L. V., Bell, D. W., Lynch, T. J., et al.: Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell-lung cancer. *J Clin Oncol*, 2007, 25, s. 567–595.
- 9 Gandara, D. R., Lara, P. N. Jr., Mack, P., et al.: Individualizing therapy for non-small-cell-lung cancer: a paradigm shift from empiric to integrated decision-making. *Clin Lung Cancer*, 2009, 10, s. 148–150.
- 10 West, H., Lienbaum, R., Harpole, D., et al.: Molecular analysis-based treatment strategies for the management of non-small-cell lung cancer. *J Thorac Oncol*, 2009, 4, s. 1029–1039.
- 11 Balak, M. N., Gong, Y., Riely, G., et al.: Novel D761Y and common secondary T790M mutations in epidermal growth factor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. *Clin Cancer Res*, 2006, 12, s. 6494–6501.
- 12 Li, S., Schmitz, K. R., Jeffrey, P. D., et al.: Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. *Cancer Cell*, 2005, 7, s. 301–311.
- 13 Peters, S., Zimmermann, S., Adjei, A. A.: Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions. *Cancer Treatment Reviews*, 2014, 40, s. 917–926.
- 14 Chan, B. A., Hughes, B. G.: Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. *Transl Lung Cancer Res*, 2015, 4, s. 36–54, doi: 10.3978/ijssn.2218-6751.2014.05.01.
- 15 Hirsh, V.: Next-generation covalent irreversible kinase inhibitors in NSCLC: Focus on afatinib. *BioDrugs*, 2015, 29, s. 167–183, doi: 10.1007/s40259-015-0130-9.
- 16 Fusek, M., Vitek, L., Blahoš, J., et al.: *Biologická léčiva*. Grada Publishing, Praha, 2012.
- 17 Sander, A., Gray, R., Perry, M. C., et al.: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. *N Engl J Med*, 2006, 355, s. 2542–2550.
- 18 Crinò, L., Dansin, E., Garrido, P., et al.: Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. *Lancet Oncol*, 2010, 11, s. 733–740, publikováno online 23. 7. 2010, doi:



- 10.1016/S1470-2045(10)70151-0.
- 19 **Herbst, R. S. – Ansari, R. – Bustin, F., et al.**: Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. *Lancet*, 2011, 377, s. 1846–1854.
- 20 **Herbst, R. – Stern, H. – Amler, L.**: Biomarker evaluation in the phase III, placebo-controlled, randomized BeTa Trial of bevacizumab

- and erlotinib for patients with advanced non-small cell lung cancer (NSCLC) after failure of standard 1st-line chemotherapy: correlation with treatment outcomes. *J Thorac Oncol*, 2009, 4, s. S323.
- 21 **Seto, T. – Kato, T. – Nishio, K., et al.**: Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (J025567): an open-label, randomised, multicentre, phase 2 study. *Lancet Oncology*, 2014, 15, s. 1236–1244, publikováno online 28. 8. 2014, [http://dx.doi.org/10.1016/S1470-2045\(14\)70381-X](http://dx.doi.org/10.1016/S1470-2045(14)70381-X).

- 22 **Stahel, R. A. – Dafni, U. – Gautschi, O., et al.**: A phase II trial of erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutations with and without T790M mutation. The Spanish Lung Cancer Group and the European Thoracic Oncology Platform BELIEF trial. 2015 European Cancer Congress, abstrakt 38A, prezentováno 28. 9. 2015.

## Testování PD-L1 – nová výzva v prediktivní diagnostice nemalobuněčných plicních karcinomů

prof. MUDr. Aleš Ryška, Ph.D. | MUDr. Markéta Nová | MUDr. Tomáš Rozkoš |  
MUDr. Helena Hornychová, Ph.D. Fingerlandův ústav patologie LF UK a FN, Hradec Králové

- 1 **Aguiar, P. N. Jr. – Santoro, I. L. – Tadokoro, H., et al.**: The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis. *Immunotherapy*, 2016, 8, s. 479–488, doi: 10.2217/imt-2015-0002.
- 2 **Cree, I. A. – Booton, R. – Cane, P., et al.**: PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation. *Histopathology*, 2016, 69, s. 177–186, doi: 10.1111/his.12996.
- 3 **Chae, Y. K. – Pan, A. – Davis, A. A., et al.**: Biomarkers for PD-1/PD-L1 blockade therapy in non-small-cell lung cancer: Is PD-L1 expression a good marker for patient selection? *Clin Lung Cancor*, 2016, doi: 10.1016/j.clcl.2016.03.011.
- 4 **Ilie, M. – Hofman, V. – Dietel, M., et al.**: Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. *Virchows Arch*, 2016, 468, s. 511–525, doi: 10.1007/s00428-016-1910-4.
- 5 **Kerr, K. M. – Nicolson, M. C.**: Non-small cell lung cancer, PD-L1, and the pathologist. *Arch Pathol Lab Med*, 2016, 140, s. 249–254, doi: 10.5858/arpa.2015-0303-SA.
- 6 **McLaughlin, J. – Han, G. – Schalper, K. A., et al.**: Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. *JAMA Oncol*, 2016, 2, s. 46–54, doi: 10.1001/jamaoncol.2015.3638.
- 7 **Mino-Kenudson, M.**: Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer? *Cancer Biol Med*, 2016, 13, s. 157–170, doi: 10.20892/jjssn.2095-3941.2016.0009.
- 8 **Parra, E. R. – Behrens, C. – Rodriguez-Canales, J., et al.**: Image analysis-based assessment of PD-L1 and tumor-associated immune cells density supports distinct intratumoral microenvironment groups in non-small cell lung carcinoma patients. *Clin Cancer Res*, 2016, doi: 10.1158/1078-0432.CCR-15-2443.
- 9 **Sacher, A. G. – Gandhi, L.**: Biomarkers for the clinical use of PD-1/PD-L1 inhibitors in non-small-cell lung cancer: a review. *JAMA Oncol*, 2016, doi: 10.1001/jamaoncol.2016.0639.
- 10 **Shimoji, M. – Shimizu, S. – Sato, K., et al.**: Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1). *Lung Cancer*, 2016, 98, s. 69–75, doi: 10.1016/j.lungcan.2016.04.021.

## Kombinace chemoterapie a ADT u naivních nemocných s karcinomem prostaty

prof. MUDr. Jindřich Fínek, Ph.D., MHA Onkologická a radioterapeutická klinika FN a LF UK, Plzeň

- 1 **Christopher, J. – Sweeney, M. B., et al.**: Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. *N Engl J Med*, 2015, 373, s. 737–746.
- 2 **Shore, N. D. – Chowdhury, S. – Villers, A., et al.**: Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. *Lancet Oncol*, 2016, 17, s. 153–163.

## Optimální sekvence léčby nemocných s metastatickým kastročně rezistentním prostatickým karcinomem

prof. MUDr. Jindřich Fínek, Ph.D., MHA Onkologická a radioterapeutická klinika FN a LF UK, Plzeň

- 1 **Mottet (Chair), J. Bellmunt, E. Briers (Patient Representative), M. Bolla, P. Cornford (Vice-chair), M. De Santis, A. Henry, S. Joniau, T. Lam, M. D. Mason, V. Matveev, H. van der Poel, T. H. van der Kwast, O. Rouvière, T. Wiegel Guidelines Associates: R. C. N. van den Bergh, T. van den Broeck, N. J. van Casteren, W. Everaerts, L. Marconi, P. Moldovan.** <http://uroweb.org/guideline/prostate-cancer>.
- 2 **Modrá kniha České onkologické společnosti, Masarykův onkologický ústav, 2016.**
- 3 **Tannock, I. F. – de Witt, R. – Berry, W. R., et al.**: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. *New Engl J Med*, 2004, 351, s. 1502–1512.
- 4 **de Bono, J. S. – Oudard, S. – Ozguroglu, M., et al.**: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. *The Lancet*, 2010, 376, s. 1147–1154.
- 5 **Kantoff, P. W. – Higano, C. S. – Shore, N. D., et al.**: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. *N Engl J Med*, 2010, 363, s. 411–422, DOI: 10.1056/NEJMoa1001294.
- 6 **Attard, G. – De Bono, J. S. – Li, W., et al.**: ERG rearrangements and association with clinical outcome in patients (pts) receiving abiraterone acetate (AA): Results from the COU-AA-302 study in chemotherapy (chemo)-naïve metastatic castration-resistant prostate cancer (mCRPC). *J Clin Oncol*, 2013 ASCO Annual Meeting Abstracts, 31, dopl, s. 5004.
- 7 **Scher, H. I. – Fizazi, K. – Saad, F., et al.**: Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study. *Journal of Clinical Oncology*, 2012 Genitourinary Cancers Symposium, 30, LBA1.
- 8 **Ryan, Ch. J. – Smith, M. R. – De Bono, J. S., et al.**: Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naïve patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). *Journal of Clinical Oncology*, 2012 ASCO Annual Meeting Abstracts, 30, LBA4518.
- 9 **Beer, T. M. – Armstrong, A. J. – Sternberg, C. N., et al.**: Enzalutamide in men with chemotherapy-naïve metastatic prostate cancer (mCRPC): Results of phase III PREVAIL study. *Journal of Clinical Oncology*, 2014 Genitourinary Cancers Symposium, 32, LBA1.

# Terapie karcinomu prsu ve světle nejnovějších poznatků – zaměřeno na systémovou terapii

MUDr. Markéta Palácová Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno

- 1 Forbes, J. F. – Cuzick, J. – Buzdar, A., et al.: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. *Lancet Oncol*, 2008, 9, s. 45–53.
- 2 Cuzick, J. – Sestak, I. – Baum, M., et al.: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. *Lancet Oncol*, 2010, 11, s. 1135–1141.
- 3 Regan, M. M. – Neven, P. – Giobbie-Hurder, A., et al.: Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. *Lancet Oncol*, 2011, 12, s. 1101–1108.
- 4 Knauer, M. – Mook, S. – Rutgers, E. J., et al.: The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. *Breast Cancer Res and Treat*, 2010, 120, s. 655–661.
- 5 Francis, P. A. – Regan, M. M. – Fleming, G. F., et al.: Adjuvant ovarian suppression in premenopausal breast cancer. *New England J Med*, 2015, 372, s. 436–446.
- 6 Pagani, O. – Regan, M. M. – Walley, B., et al.: Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. *New England J Med*, 2014, 371, s. 107–118.
- 7 Regan, M. M. – Pagani, O. – Francis, P. A., et al.: Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials. *Breast Cancer Res and Treat*, 2015, 154, s. 275–286.
- 8 Davies, C. – Pan, H. – Godwin, J., et al.: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of estrogen receptor-positive breast cancer: ATLAS, a randomized trial. *Lancet*, 2013, 381, s. 805–816.
- 9 Gray, R. – Rea, D. – Handley, K., et al.: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6953 women with early breast cancer. *J Clin Oncol*, 2013, 31 (dopl.), abstrakt 5.
- 10 Diates, A. S. – Winer, E. P. – Goldhirsch, A., et al.: Tailoring therapies – improving the management of early breast cancer: St.Gallen international expert consensus on the primary therapy of early breast cancer 2015. *Annals of Oncol*, 2015, 26, s. 1533–1546.
- 11 Goss, P. E. – Ingle, J. N. – Pritchard, K. I., et al.: Extending aromatase-inhibitor adjuvant therapy to 10 years. *New England J Med*, červen 2016.
- 12 Hulman, L. N. – Cirrincione, C. T. – Berry, D. A., et al.: Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: CALGB 40101. *J Clin Oncol*, 2012, 30, s. 4071–4076.
- 13 Tolaney, S. M. – Barry, W. T. – Dang, C. T., et al.: Adjuvant paclitaxel and trastuzumab for node-negative, HER2 positive breast cancer. *N Engl J Med*, 2015, 372, s. 134–141.
- 14 Rastogi, P. – Anderson, S. J. – Bear, H. D., et al.: Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. *J Clin Oncol*, 2008, 26, s. 778–785.
- 15 von Minckwitz, G. – Untch, M. – Blohmer, J. U., et al.: Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. *J Clin Oncol*, 2012, 30, s. 1796–1804.
- 16 Cortazar, P. – Zhang, L. – Untch, M., et al.: Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. *Lancet*, 2014, 384, s. 164–172.
- 17 Siegel, R. L. – Miller, K. D. – Jemal, A.: Cancer statistics, 2015. *CA Cancer J Clin*, 2015, 65, s. 5–29.
- 18 Clarke, C. A. – Keegan, T. H. – Yang, J., et al.: Age-specific incidence of breast cancer subtypes: Understanding the black-white crossover. *J Natl Cancer Inst*, 2012, 104, s. 1094–1101.
- 19 Lobbezoo, D. J. – van Kampen, R. J. – Voogd, A. C., et al.: Prognosis of metastatic breast cancer subtypes: The hormone receptor/HER2-positive subtype is associated with the most favorable outcome. *Breast Cancer Res and Treat*, 2013, 141, s. 507–514.
- 20 Cardoso, F. – Costa, A. – Norton, L., et al.: ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). *Annals of Oncol*, 2014, 25, s. 1871–1888.
- 21 Rugo, H. S. – Rumble, R. B. – Maceese, E., et al.: Endocrine therapy for hormone receptor-positive metastatic breast cancer: American society of clinical oncology guideline. *J Clin Oncol*, 2016, 34, online.

## Možnosti léčby pokročilého karcinomu prsu při výskytu hormonální rezistence

MUDr. Zdeněk Linke Onkologická klinika FN Motol, Praha

- 1 Dostupné z: [www.onconet.cz/index.php?pg=aktuality&id=180](http://www.onconet.cz/index.php?pg=aktuality&id=180), vyhledáno 28. 7. 2016.
- 2 ESO-ESMO 2<sup>nd</sup> international consensus guidelines for advanced breast cancer (ABC2), 2014.
- 3 Dalmiau, E. – Armengol-Alonso, A., et al.: Current status of hormone therapy in patients with hormone receptor positive advanced breast cancer. *The Breast*, 2014, 23, s. 710–720.
- 4 DiLeo, A. – Jerusalem, G. – Petruzella, L., et al.: Results of CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. *J Clin Oncol*, 2010, 28, s. 4594–4600.
- 5 Osborne, C. K. – Neven, P. – Dirix, L. Y., et al.: Gefitinib or placebo in combination with tamoxifen in patient with hormone receptor-positive metastatic breast cancer: a randomized phase II study. *Clin Cancer Res*, 2011, 17, s. 1147–1159.
- 6 Johnston, S. – Pipen, J. Jr., et al.: Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. *J Clin Oncol*, 2009, 27, s. 5538–5546.
- 7 Kaufman, B. – Mackey, J. R., et al.: Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. *J Clin Oncol*, 2009, 27, s. 5529–5537.
- 8 Andre, F. – Cortés, J.: Rationale for targeting fibroblast growth factor receptor signaling in breast cancer. *Breast Cancer Res Treat*, 2015, 150, s. 1–8.
- 9 Krop, I. – Johnston, S. – Mayer, I. A., et al.: The FERG phase II study of the PI3K inhibitor pictilisib (GCD-0941) plus fulvestrant vs fulvestrant plus placebo in patients with ER+, aromatase inhibitor (AI)-resistant advanced or metastatic breast cancer. San Antonio, DOI: 10.1158/1538-7445.SABCS14-S2-02, květen 2015.
- 10 Phase III study of BMK120/placebo with fulvestrant in postmenopausal patients with hormone receptor positive HER2-negative locally advanced or metastatic breast cancer refractory to aromatase inhibitors (BELLE-2). Dostupné z: <https://clinicaltrials.gov/ct2/show/NCT01610284>, vyhledáno 19. 4. 2016.
- 11 Bachelot, T. – Bourgie, C. – Cropet, C., et al.: TARMAD: A GINECO randomized phase II trial of everolimus in combination with tamoxifen versus tamoxifen alone in patients (pts) with hormone-receptor positive, HER2 negative metastatic breast Cancer (MBC) with prior exposure to aromatase inhibitor (AI). *Cancer Res*, 2010, 70 (dopl.), abstrakt, 51–56.
- 12 Piccart, M. – Hortobagyi, G. N. – Campone, M., et al.: Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. *Ann Oncol*, 2014, 25, s. 2357–2362.
- 13 Baselga, J. – Semiglazov, V. – van Dam, P., et al.: Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. *J Clin Oncol*, 2009, 27, s. 2630–2637.
- 14 A study a palbociclib (PD-0332991) + letrozole vs. letrozole for 1st line treatment of postmenopausal women with ER+/HER2-advanced breast cancer (PALOMA-2). National Cancer Institute at the National Institutes of Health Clinical Trials. Dostupné z: <https://clinicaltrials.gov/ct2/show/NCT01740427>, vyhledáno 12. 8. 2015.
- 15 Palbociclib (PD-0332991) combined with fulvestrant in hormone receptor+ HER2-negative metastatic breast cancer after endocrine failure (PALOMA-3). National Cancer Institute at the National Institutes of Health Clinical Trials. Dostupné z: <https://clinicaltrials.gov/ct2/show/NCT01942135>, vyhledáno 12. 8. 2015.
- 16 Byrd, J. C. – Peterson, B. L. – Gabrilove, J., et al.: Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour infusion of flavopiridol: results of Cancer and Leukemia Group B study 19805. *Clin Cancer Res*, 2005, 11, s. 4176–4181.
- 17 Fry, D. W. – Bedford, B. C. – Keller, P. R., et al.: Cell cycle and biochemical effects of PD0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6. *J Biol Chem*, 2001, 276, s. 16617–16623.
- 18 Sun, Y. – Li, Y. X. – Wu, H. L., et al.: Effects of an indolocarbazole-derived CDK4 inhibitor on breast cancer cells. *J Cancer*, 2011, 2, s. 36–51.
- 19 Fin, R. S. – Feriny, J. – Conklin, D., et al.: PD0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. *Breast Cancer Res*, 2009, 11, s. R77.
- 20 Flaherty, K. T. – Lorusso, P. M. – Demichele, A., et al.: Phase I, dose-escalation trial of the oral cyclin dependent kinase 4/6 inhibitor PD0332991, administered using a 21-day schedule in patients with advanced cancer. *Clin Cancer Res*, 2012, 18, s. 568–576.
- 21 Demichele, A. – Clark, A. S. – Heitjan, D., et al.: A phase II trial of an oral CDK 4/6 inhibitors, PD0332991, in advanced breast cancer. *J Clin Oncol*, 2013, 31, abstrakt 519.
- 22 Finn, R. S. – Crown, J. P. – Lang, I., et al.: Final results of a randomized phase II study of PD0332991, a cyclin-dependent kinase (CDK-4/6 inhibitor), in combination with letrozole vs. letrozole alone as first line treatment of HR+/HER2- advanced breast cancer (PALOMA-1; TRIO-18). Prezentováno na American Association for Cancer Research, San Diego, CA, 2014, abstrakt 1000.
- 23 Phase III study of palbociclib (PD-0332991) in combination with exemestane versus chemotherapy capecitabine in hormonal receptor (HR) positive/HER2 negative metastatic breast cancer (MBC) patients with resistance to non-steroidal aromatase inhibitor (PEARL). Dostupné z: <https://clinicaltrials.gov/ct2/show/NCT02028507>, vyhledáno 16. 5. 2014.
- 24 PD-0332991 and anastrozole for stage 2 and 3 metastrogen receptor positive and HER2 negative breast cancer. National Cancer Institute at the National Institutes of Health Clinical Trials. Dostupné z: <https://clinicaltrials.gov/ct2/show/NCT01723774>, vyhledáno 12. 8. 2015.
- 25 A study of palbociclib in addition to standard endocrine treatment in hormone receptor positive Her2 normal patients with residual disease after neoadjuvant chemotherapy and surgery (PENLOPE-B). Dostupné z: <https://clinicaltrials.gov/ct2/show/NCT01864746>, vyhledáno 16. 5. 2014.
- 26 Palbociclib + endocrine therapy for HR+ BrCa. National Cancer Institute at the National Institutes of Health Clinical Trials. Dostupné z: <https://clinicaltrials.gov/ct2/show/NCT0204857>, vyhledáno 12. 8. 2015.
- 27 PD0332991/paclitaxel in advanced breast cancer. National Cancer Institute at the National Institutes of Health Clinical Trials. Dostupné z: <https://clinicaltrials.gov/show/NCT0320592>, vyhledáno 12. 8. 2015.
- 28 Infante, J. R. – Shapiro, G. I. – Witteveen, P. O., et al.: Phase 1 multicenter, open-label, dose escalation study of LEE011, an oral inhibitor of cyclin-dependent kinase 4/6, in patients with advanced solid tumors and lymphomas. *Mol Cancer Ther*, 2013, 12, abstrakt A276.
- 29 Study of efficacy and safety in premenopausal women with advanced breast cancer. Dostupné z: <https://clinicaltrials.gov/show/NCT01958021>, vyhledáno 27. 5. 2014.
- 30 A pharmacodynamics pre-surgical study of LEE011 in early breast cancer (MONALEESA-1). Dostupné z: <https://clinicaltrials.gov/show/NCT01919229>, vyhledáno 27. 5. 2014.
- 31 Bardia, A. – Modi, S. – Chavez-MacGregor, M., et al.: A Phase Ib/II study of LEE011, everolimus and exemestane in postmenopausal women with ER+/HER- metastatic breast cancer. Prezentováno na ASCO, květen 2014, abstrakt 535.

- 32 Juric, D. – Hamilton, E. – Estévez, L., et al.: Phase Ib/II study of LEE011 and BYL719 and letrozole in ER+, HER- breast cancer: safety, preliminary efficacy and molecular analysis. *Cancer Res*, 2015, 75, abstrakt P5-19-24.
- 33 Patnaik, A. – Rosen, L. S. – Tolaney, S. M., et al.: Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with metastatic breast cancer (abstract CT232). Prezentováno na American Association for Cancer Research, San Diego CA, duben 2014.
- 34 Rosen, L. S.: Activity of LY2835219, as cell cycle inhibitor selective for CDK4 and CDK6, in combination with fulvestrant for patients with hormone receptor positive (HR+) metastatic breast cancer. Prezentováno na ASCO, Chicago, květen 2014, abstrakt 534.
- 35 A study of LY2835219 in combination with therapies for breast cancer that has spread. Dostupné z: <https://clinicaltrials.gov/ct2/show/NCT02057133>, vyhledáno 27. 5. 2014.
- 36 A study of LY2835219 in participants with previously treated breast cancer that has spread. National Cancer Institute at the National Institute of Health Clinical Trials. Dostupné z: <https://clinicaltrials.gov/ct2/show/NCT01394016>, vyhledáno 12. 8. 2015.
- 37 A study of LY2835219 in combination with therapies for breast cancer that has spread. Dostupné z: <https://clinicaltrials.gov/ct2/show/NCT02057133>, vyhledáno 27. 5. 2014.
- 38 A phase 2 neoadjuvant study of abemaciclib (LY2835219) in postmenopausal women with hormone receptor positive, HER2 negative (neoMONARCH). Dostupné z: <https://clinicaltrials.gov/ct2/show/NCT02441946?term=abemaciclib&rank=3>, vyhledáno 15. 5. 2014.
- 39 A study of abemaciclib (LY2835219) in participants with breast cancer that has spread to the brain. Dostupné z: <https://clinicaltrials.gov/ct2/show/NCT02441946?term=abemaciclib&rank=3>, vyhledáno 15. 5. 2015.
- 40 Piccart, M.: *Advances in endocrine therapy and endocrine resistance*. ABC2, 2013, Lisabon.
- 41 MONALEESA-7 LEE011 A phase III study of efficacy and safety in premenopausal women with advanced HR+/HER2- breast cancer. Dostupné z: [www.trials.novartis.com/en/clinical-trials/us-oncology/oncology/monaleesa/monaleesa-7/overview/#sthash.Em1bfYLS.dpuf](http://www.trials.novartis.com/en/clinical-trials/us-oncology/oncology/monaleesa/monaleesa-7/overview/#sthash.Em1bfYLS.dpuf), vyhledáno 8. 8. 2016.
- 42 A study of abemaciclib (LY2835219) combined with fulvestrant in women with hormone receptor positive HER2 negative breast cancer (MONARCH 2). Dostupné z: <https://clinicaltrials.gov/ct2/show/NCT02107703>, vyhledáno 8. 8. 2016.
- 43 A trial of fulvestrant with AZD2014 or everolimus for advanced breast cancer (MANTA). Dostupné z: <http://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-fulvestrant-azd2014-everolimus-advanced-breast-cancer-manta#2pxWxjYV8b5frso.99>, vyhledáno 8. 8. 2016.
- 44 PIPA: combination of PI3 kinase inhibitors and palbociclib (PIPA). Dostupné z: <https://clinicaltrials.gov/ct2/show/NCT02389842>, vyhledáno 8. 8. 2016.
- 45 A phase Ib/II, multicenter study of the combination of LEE011 and BYL719 with letrozole in adult patients with advanced ER+ breast cancer. Dostupné z: <http://adisinsight.springer.com/trials/700233681>, vyhledáno 8. 8. 2016.
- 46 Finn, R. S. – Crown, J. P. – Lang I., et al.: Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (BC). *Cancer Res*, 2012, 72 (dopl.), abstrakt S1–S6.

## Lipegfilgrastim v prevenci febrilní neutropenie ve studii z klinické praxe NADIR

prof. MUDr. Jindřich Fínek, Ph.D., MHA Onkologická a radioterapeutická klinika FN a LF UK, Plzeň

- 1 Molineux, G.: Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients. *Anticancer Drugs*, 2003, 14, s. 259–264.
- 2 Johnston, E. – Crawford, J. – Blackwell, S., et al.: Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. *J Clin Oncol*, 2000, 18, s. 2522–2528.
- 3 Molineux, G. – Kinstler, O. – Briddell, B., et al.: A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. *Exp Hematol*, 1999, 27, s. 1724–1734.
- 4 Allen, R. C. – Mireles, M. A. – Welch, W.: Phase I study comparing daily filgrastim and single dose sustained-duration filgrastim in normal volunteers: effects on neutrophil respiratory burst activities (abstract no. 3944). *Blood*, 1999, 94, s. 172.
- 5 Seiberling, M., et al.: *Research report. XM22-01-CH*. Mannheim, Německo, Biogenerix, 2009.
- 6 Lonquex. Hodnotící zpráva. EMA/371234/2013.
- 7 Seiberling, M., et al.: *Research report. XM22-05-CH*. Mannheim, Německo, Biogenerix, 2009.
- 8 *Micromedex* 9/2014, AISLP v. 3.2014.
- 9 SPC Lonquex, [www.sukl.cz](http://www.sukl.cz).
- 10 Bondarenko, I. – Gladkov, O. A. – Elsaesser, R., et al.: Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy. *BMC Cancer*, 2013, 13, s. 386.
- 11 Kurbacher, C. M. – Fietz, T. – Diel, I. J., et al.: NADIR: A non-interventional study on the prophylaxis of chemotherapy-induced neutropenia using lipegfilgrastim – first interim analysis. *Oncol Res Treat*, 2015, 38, s. 221–229.

## Kudy v léčbě metastatického maligního melanomu

MUDr. Ivana Krajsová, MBA Dermatovenerologická klinika VFN a 1. LF UK

- 1 Zhu, Z. – Liu, W. – Gotlieb, V.: The rapidly evolving therapies for advanced melanoma – Towards immunotherapy, molecular targeted therapy and beyond. *Crit Rev Oncol Hematol*, 2016, 99, s. 91–99.
- 2 Trinh, V. A. – Hagen, B.: Ipilimumab for advanced melanoma. *J Oncol Pharm Practice*, 2012, 19, s. 195–201.
- 3 Wolchok, J. D. – Weber, J. S. – Maio, M., et al.: Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. *Ann Oncol*, 2013, 8, s. 2174–2180.
- 4 Schadendorf, D. – Hodi, F. S. – Robert, C., et al.: Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. *J Clin Oncol*, 2015, doi:10.1200/JCO.2014.56.2736.
- 5 Topalian, S. L. – Sznol, M. – McDermott, D. F., et al.: Survival durable tumor remission and long term safety in patients with advanced melanoma receiving nivolumab. *J Clin Oncol*, 2014, 32, s. 1020–1030.
- 6 Weber, S. J. – D'Angelo, S. P. – Minor, D., et al.: Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomized, controlled, open label phase 3 trial. *Lancet Oncol*, 2015, 16, s. 375–384.
- 7 Robert, C. – Schachter, J. – Long, G. V., et al.: Pembrolizumab versus ipilimumab in advanced melanoma. *N Engl J Med*, 2015, 372, s. 2521–2532.
- 8 Larkin, J. – Chiarion-Sileni, V. – Gonzales, R., et al.: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. *N Engl J Med*, 2015, 373, s. 23–34.
- 9 Hodi, F. S. – Hwu, W. J. – Kefford, R., et al.: Evaluation of immune-related response criteria and RECIST 1.1 in patients with advanced melanoma treated with pembrolizumab. *JCO*, 7. 3. 2016, doi: 10.1200/JCO.2015.64.0391.
- 10 Chapman, P. B. – Hauschild, A. – Robert, C., et al.: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. *N Engl J Med*, 2011, 364, s. 2507–2516.
- 11 McArthur, G. A. – Chapman, P. B. – Robert, C., et al.: Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. *Lancet Oncol*, 2014, 15, s. 323–332.
- 12 Hauschild, A. – Grob, J. J. – Demidov, L. V., et al.: Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. *Lancet*, 2012, 380, s. 358–365.
- 13 Long, G. – Stroyakovskiy, D. – Gogas, H., et al.: Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. *N Engl J Med*, 2014, 371, s. 1877–1888.
- 14 Larkin, J. – Ascierto, P. A. – Dreno, B., et al.: Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. *N Engl J Med*, 2014, 371, s. 1867–1876.
- 15 Robert, C. – Karaszewska, B. – Schachter, J., et al.: Improved overall survival in melanoma with combined dabrafenib and trametinib. *N Engl J Med*, 2015, 372, s. 30–39.
- 16 Welsh, S. J. – Corrie, P. G.: Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. *Ther Adv Med Oncol*, 2015, 7, s. 122–136.
- 17 Ibrahim, R. – Berman, D. – DePri, V., et al.: Ipilimumab safety profile: summary of findings from completed trials in advanced melanoma. *J Clin Oncol*, 2011, 29 (dopl.), abstrakt 8583.

## Melanom v roce 2016: diagnostika a možnosti léčby

Rozhovor Dany Frantálové s Petrem Arenbergerem, Ivanou Krajsovou a Radkem Lakomým

- 1 Barbour, A. P. – Tang, Y. H. – Armour, N., et al.: BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy. *Eur J Cancer*, 2014, 50, s. 2668–2676, doi: 10.1016/j.ejca.2014.06.009, Epub 25. 7. 2014.
- 2 Larkin, J. – Lao, C. D., et al.: Efficacy and safety of nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma. A pooled analysis of 4 clinical trials. *JAMA Oncol*, 2015, 1, s. 433–440.
- 3 Dhillon, S.: Dabrafenib plus trametinib: a review in advanced melanoma with a BRAF (V600) mutation. *Target Oncol*, 2016, 11, s. 417–428.
- 4 Wolchok, J.: Checkmate 067. *J Clin Oncol*, 2016, 34, abstrakt 9505.



# Sarkomy měkkých tkání – vzácné tumory s nutností léčby v centrech

MUDr. Kateřina Kopečková Onkologická klinika 2. LF UK, FN Motol, Praha  
RNDr. Lenka Krsková, Ph.D. Ústav patologie a molekulární medicíny 2. LF UK a FN Motol, Praha

- Cuppens T. – Tuyaerts, S. – Amant, F.: Potential therapeutic targets in uterine sarcomas. *Sarcoma* 2015, Article ID 243298, s. 1–14, doi.org/10.1155/2015/243298.
- van Maldegem, A. M. – Bovée, J. V. M. G. – Peterse, E. F. P., et al.: Ewing sarcoma: The clinical relevance of the insulin-like growth factor 1 and the poly-ADP-ribose-polymerase pathway. *Eur J Cancer*, 2016, 53, s. 171–180.
- The ESMO/European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*, 2014, 25 (S3), s. iii102–iii112, Doi:10.1093/annonc/mdl254.
- Cidre-Aranaz, F. – Alfonso, J.: EWS/FLI 1 target genes and therapeutic opportunities in Ewing sarcoma. *Front Oncol*, 2015, 5, s. 162, Doi: 10.3389/fonc.2015.00162.
- Ehnman, M. – Larsson, O.: Microenvironmental targets in sarcoma. *Front Oncol*, 2015, 5, s. 248, Doi: 10.3389/fonc.2015.00248.
- Ruiz-Mesa, C. – Goldberg, J. M. – Coronado Munoz, A. J., et al.: Rhabdomyosarcoma in Adults: New Perspectives on Therapy. *Curr Treat Options in Oncol*, 2015, 16, s. 27, Doi 10.1007/s11864-015-0342-8.
- Kanojia, D. – Nagata, Y. – Gard, M.: Genomic landscape of liposarcoma. *Oncotarget*, 2015, 6, s. 42429–42444.
- Wardelmann, E. – Schildhaus, H. U. – Merkelbach-Bruse, S.: Soft tissue sarcoma: from molecular diagnosis to selection of treatment. Pathological diagnosis of soft tissue sarcoma amid molecular biology and targeted therapies. *Ann Oncol*, 2010, 21, s. vii265–vii269, Doi: 10.1093/annonc/mdlq381.
- Noujaim, J. – Thway, K. – Fischer, C.: Dermatofibrosarcoma protuberans: from translocation to targeted therapy. *Cancer Biol Med*, 2015, 10, s. 375–384.
- Kovar, H. – Amatruda, J. – Brunet, E.: The second European interdisciplinary Ewing sarcoma research summit – A joint effort to deconstructing the multiple layers of a complex disease. *Oncotarget*, 2016, s. 1–12.
- Noujaim, J. – Thway, K. – Sheri, A., et al.: Histology-driven therapy: The importance of diagnostic accuracy in guiding systemic therapy of soft tissue tumors. *International Journal of Surgical Pathology*, 2016, 24, s. 5–15.
- Dickson, M. – Tap, W. – Keohan, M., et al.: Phase II trial of the CDK4 inhibitor PD033991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. *J Clin Oncol*, 2013, 31, s. 2024–2028.
- Stacchiotti, S. – Marrari, A. – Tamborini, E., et al.: Response to imatinib plus sirolimus in advanced chordoma. *Ann Oncol*, 2009, 20, s. 1886–1894.
- Bompas, E. – Le Cesne, A. – Tresch Bruneel, E., et al.: Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO). *Ann Oncol*, 2015, 26, s. 2168–2173.
- Stacchiotti, S. – Tamborini, E. – Lo Vullo, S., et al.: Phase II study on lapatinib in advanced EGFR-positive chordoma. *Ann Oncol*, 2013, 24, s. 1931–1936.
- Butrynski, J. – D'Adamo, D. – Hornick, J., et al.: Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. *N Engl J Med*, 2010, 363, s. 1727–1733.
- Janinis, J. – Patriki, M. – Vini, L., et al.: The pharmacological treatment of aggressive fibromatosis: a systematic review. *Ann Oncol*, 2003, 14, s. 181–190.
- ESMO/ European Sarcomas Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*, 2014, 25 (S3), s. iii102–iii112.
- Shdeikhbahaei, S. – Marcus, C. – Hafezi-Nejad, N., et al.: Value of FDG PET/CT in patient management and outcome of skeletal and soft tissue sarcoma. *PET Clin*, 2015, 10, s. 375–393.
- Jernigan, E. W. – Esther, R. J.: Soft tissue masses for the general orthopedic surgeon. *Orthop Clin N Am*, 2015, 46, s. 417–428.
- Schöffski, P. – Ray-Coquard, I. L. – Cioffi, A., et al.: Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. *Lancet Oncol*, 2011, 12, s. 1045–1052.

## Cílená léčba karcinomu ovaria – současnost a novinky

doc. MUDr. Michal Zikán, Ph.D.

Onkogynekologické centrum, Gynekologicko-porodnická klinika 1. LF UK a VFN, Praha

- SPC Avastin, dostupné z: [http://www.ema.europa.eu/docs/cs\\_CZ/document\\_library/EPAR\\_-\\_Product\\_Information/human/000582/WC500029271.pdf](http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/000582/WC500029271.pdf), vyhledáno 22. 6. 2016.
- <http://www.svod.cz>.
- Burger, R. A. – Brady, M. F. – Bookman, M. A., et al.: Incorporation of bevacizumab in the primary treatment of ovarian cancer. *N Engl J Med*, 2011, 365, s. 2473–2483.
- Oza, A. M. – Cook, A. D. – Pfisterer, J., et al.: ICON7 trial investigators. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. *Lancet Oncol*, 2015, 16, s. 928–936.
- Aghajanian, C. – Goff, B. – Nycum, L. R., et al.: Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. *Gynecol Oncol*, 2015, 139, s. 10–16.
- Poveda, A. M. – Selle, F. – Hilpert, F., et al.: Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: Analysis by chemotherapy cohort of the randomized phase III AURELIA trial. *J Clin Oncol*, 2015, 33, s. 3836–3838.
- Pfisterer, J. – Plante, M. – Vergote, I., et al.: Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. *J Clin Oncol*, 2006, 24, s. 4699–4707.
- Greer, R. A. – Sill, M. W. – Monk, B. J., et al.: Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group study. *J Clin Oncol*, 2007, 28, s. 5156–5171.
- García, A. A. – Hirte, H. – Fleming, G., et al.: Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia. *J Clin Oncol*, 2008, 26, s. 76–82.
- Cannistra, S. A. – Matulonis, U. A. – Penson, R. T., et al.: Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. *J Clin Oncol*, 2007, 25, s. 5180–5186.
- Aghajanian, C. – Blank, S. V. – Goff, B. A., et al.: OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. *J Clin Oncol*, 2012, 30, s. 2039–2045.
- Tewari, K. S. – Sill, M. W. – Long, H. J., et al.: Improved survival with bevacizumab in advanced cervical cancer. *N Engl J Med*, 2014, 370, s. 734–743.
- Phippen, N. T. – Leath, C. A.: Bevacizumab in recurrent, persistent, or advanced stage carcinoma of the cervix: is it cost-effective? *Gynecol Oncol*, 2015, 136, s. 43–47.
- Kitagawa, R. – Katsumata, N. – Shibata, T., et al.: A randomized, phase III trial of paclitaxel plus carboplatin (TC) versus paclitaxel plus cisplatin (TP) in stage IVb, persistent or recurrent cervical cancer: Japan Clinical Oncology Group study (JCOG505) (abstrakt). *J Clin Oncol*, 2012, 30, abstrakt 5006.
- Plummer, R.: Perspective on the pipeline of drugs being developed with modulation of DNA damage as a target. *Clin Cancer Res*, 2010, 16, s. 4527–4531.
- Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. *Nature*, 2011, 474, s. 609–615.
- Rouleau, M. – Patel, A. – Hendzel, M. J., et al.: PARP inhibition: PARP1 and beyond. *Nat Rev Cancer*, 2010, 10, s. 293–301.
- Chen, S. – Parmigiani, G.: Meta-analysis of BRCA1 and BRCA2 penetrance. *J Clin Oncol*, 2007, 25, s. 1329–1333.
- Tan, D. S. – Rothermundt, C. – Thomas, K., et al.: “BRCAness” syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. *J Clin Oncol*, 2008, 26, s. 5530–5536.
- Schultz, N. – Lopez, E. – Saleh-Gohari, N., et al.: Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination. *Nucleic Acids Res*, 2003, 31, s. 4959–4964.
- Liu, J. F. – Tolaney, S. M. – Birrer, M., et al.: A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. *Eur J Cancer*, 2013, 49, s. 2972–2978.
- Ledermann, J. – Harter, P. – Gourley, C., et al.: Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. *Lancet Oncol*, 2014, 15, s. 852–861.
- Ledermann, J. – Harter, P. – Gourley, C., et al.: Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. *N Engl J Med*, 2012, 366, s. 1382–1392.

## ESMO 2016: léčba metastatického kolorektálního karcinomu

MUDr. Jiří Tomášek, Ph.D. Klinika komplexní onkologické péče MOÚ, Brno

- Tran, B. – Kopetz, S. – Tie, J., et al.: Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. *Cancer*, 2011, 117, s. 4623–4632.
- Le, D. T. – Uram, J. N. – Wang, H., et al.: PD-1 blockade in tumors with mismatch-repair deficiency. *N Engl J Med*, 2015, 372, s. 2509–2520.
- Guiney, J. – Dienstmann, R. – Wang, B., et al.: The consensus molecular subtypes of colorectal cancer. *Nat Med*, 2015, 21, s. 1350–1356.
- Adam, R. – De Gramont, A. – Figueras, J., et al.: The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. *Oncologist*, 2012, 17, s. 1225–1239.

# Novinky v systémové léčbě pokročilého karcinomu ledvin

MUDr. Kateřina Kopečková Onkologická klinika, II. LF UK a FN Motol, Praha

- 1 WHO, International Agency for Research on Cancer. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. <http://globocan.iarc.fr/Default.aspx>, IARC 2016, Francie.
- 2 www.svod. cz.
- 3 Motzer, R. J. – Escudier, B. – McDermott, D. F., et al.: Nivolumab versus everolimus in advanced renal-cell carcinoma. *N Engl J Med*, 2015, 373, s. 1803–1813.
- 4 Curran, M. A. – Montalvo, W. – Yagita, H., et al.: PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. *Proc Natl Acad Sci U S A*, 2010, 107, s. 4275–4280.
- 5 Hammers, H. J. – Plimack, E. R. – Infante, J. R., et al.: Expanded cohort results from CheckMate 016: A phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). *J Clin Oncol*, 2015, 33 (dopl.), abstrakt 4516.
- 6 Ko, J. S. – Zea, A. H. – Rini, B., et al.: Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. *Clin Cancer Res*, 2009, 15, s. 2148–2157.
- 7 Lin, J. C. – Liu, C. L. – Lee, J. J., et al.: Sorafenib induces autophagy and suppresses activation of human macrophage. *Int Immunopharmacol*, 2013, 15, s. 333–339.
- 8 Motzer, R. J. – Hutson, T. E. – Glen, H., et al.: Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised phase 2, open-label, multicentre trial. *Lancet Oncol*, [http://dx.doi.org/10.1016/S1473-0166\(15\)290-299](http://dx.doi.org/10.1016/S1473-0166(15)290-299).
- 9 Choueiri, T. K. – Escudier, B. – Powles, T., et al.: For the METEOR investigators. Cabozantinib versus everolimus in advanced renal-cell carcinoma. *N Engl J Med*, publikováno online 25. 9. 2015.

## Fixní kombinace oxycodon/naloxon v léčbě kombinované bolesti – klinická kazuistika

doc. MUDr. Luboš Holubec, Ph.D. Biomedicínské centrum, LF v Plzni, UK Praha,

Oddělení klinické onkologie, Nemocnice Na Homolce, Praha

MUDr. Lenka Lisnerová | MUDr. Martin Šalanda

Oddělení klinické onkologie, Nemocnice Na Homolce, Praha

MUDr. Václav Liška, Ph.D. Biomedicínské centrum, LF v Plzni, UK Praha

- 1 Morlion, B. – Clemens, K. E. – Dunlop, W.: Quality of life and healthcare resource in patients receiving opioids for chronic pain: a review of the place of oxycodone/naloxone. *Clin Drug Investig*, 2015, 35, s. 1–11.
- 2 Vrba, I.: Fixní kombinace oxycodonu s naloxonem – nový silný opioid s prevencí vzniku zácpy vyvolané opioidy. *Remedia*, 2014, 24, s. 279–284.
- 3 Hakl, M. – Ševčík, P.: Novinky v léčbě chronické bolesti. *Klinická farmakologie a farmacie*, 2009, 23, s. 179–180.
- 4 Hesselbarth, S. – Hermanns, K. – Oepen, P.: Prolonged-release oxycodone/naloxone in opioid-naïve patients – subgroup analysis of a prospective observational study. *Expert Opin Pharmacother*, 2015, 16, s. 457–464.
- 5 Breivik, H. – Heryn, N. – Collett, B., et al.: Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. *Ann Oncol*, 2009, 20, s. 1420–1433.
- 6 Breivik, H. – Collett, B. – Ventafridda, V., et al.: Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. *Eur J Pain*, 2006, 10, s. 287–333.
- 7 Tofthagen, C. S. – McMillan, S. C.: Pain, neuropathic symptoms, and physical and mental well-being in persons with cancer. *Cancer Nurs*, 2010, 33, s. 436–444.
- 8 McMillan, S. C.: Assessing and managing opiate-induced constipation in adults with cancer. *Cancer Control*, 2004, 11, s. 3–9.
- 9 Hermanns, K. – Junker, U. – Nolte, T.: Prolonged-release oxycodone/naloxone in the treatment of neuropathic pain – results from a large observational study. *Expert Opin Pharmacother*, 2012, 13, s. 299–311.
- 10 Ahmedzai, S. H. – Leppert, W. – Janecki, M., et al.: Long-term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer pain. *Support Care Cancer*, 2015, 23, s. 823–830.
- 11 Baron, R. – Jansen, J. P. – Binder, A., et al.: Tolerability, safety, and quality of life with tapentadol prolonged release (PR) compared with oxycodone/naloxone PR in patients with severe chronic low back pain with a neuropathic component: A randomized, controlled, open-label, phase 3b/4 trial. *Pain Pract*, 2016, 16, s. 600–619.
- 12 Blagden, M. – Hafer, J. – Duerr, H., et al.: Long-term evaluation of combined prolonged-release oxycodone and naloxone in patients with moderate-to-severe chronic pain: pooled analysis of extension phases of two Phase III trials. *Neurogastroenterol Motil*, 2014, 26, s. 1792–1801.
- 13 Löwenstein, O. – Leyendecker, P. – Lux, E. A., et al.: Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials. *BMC Clin Pharmacol*, 2010, 29, s. 10–12.
- 14 Sanders, M. – Jones, S. – Löwenstein, O., et al.: New formulation of sustained release naloxone can reverse opioid induced constipation without compromising the desired opioid effects. *Pain Med*, 2015, 16, s. 1540–1550.
- 15 Dunlop, W. – Uhl, R. – Khan, I., et al.: Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate-to-severe non-malignant pain and opioid-induced constipation: a UK cost-utility analysis. *J Med Econ*, 2012, 15, s. 564–575.
- 16 Schutter, U. – Grubery, S. – Meyer, C., et al.: Innovative pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: a large observational study under conditions of daily practice. *Curr Med Res Opin*, 2010, 26, s. 1377–1387.

## ASCO 2016: Avastin ve světle novinek

MUDr. Tomáš Svoboda, Ph.D. Komplexní onkologické centrum FN, Plzeň

- 1 Delaloge, S. – Pérol, D. – Brain, E., et al.: Overall survival of patients with HER2-negative metastatic breast cancer treated with a first-line paclitaxel with or without bevacizumab in real-life setting: results of a multicenter national observational study. 2016 ASCO Annual Meeting. *ASCO 2016*, abstrakt 1013, doi: <http://meetinglibrary.asco.org/content/168209-176>.
- 2 Lenz, H. J. – Lee, F. Ch. – Yau, L., et al.: MAVERICC, a phase 2 study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV with biomarker stratification as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC). *ASCO 2016*, abstrakt 3515. Lenz, H. J. – Lee, F. Ch. – Yau, L., et al.: MAVERICC, a phase 2 study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV with biomarker stratification as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC). *J Clin Oncol*, 2016, Gastrointestinal Cancers Symposium, dopl. 2016, s. 493.
- 3 Malka, D. – Metges, J. P. – Elias, D., et al.: Bevacizumab plus chemotherapy (bev/CT) as first-line therapy for patients with potentially resectable metastatic colorectal cancer (mCRC): Final results of the French noninterventional PICASSO study. *J Clin Oncol*, 2016, dopl., abstrakt 3554.
- 4 Bendell, J. C. – Tan, B. R. – Reeves, J. A., et al.: Overall response rate (ORR) in STEAM, a randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab (BEV) vs FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC). *ASCO GI 2016*. *J Clin Oncol*, 2016, dopl., s. 492.
- 5 Raghav, K. P. S. – Overman, M. J. – Yu, R., et al.: HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer. *J Clin Oncol*, 2016 ASCO Annual Meeting, dopl., abstrakt 3517.
- 6 Francois, E. – Kim, S. Ch. H. – Burki, F., et al.: Bevacizumab plus chemotherapy as first-line therapy for elderly patients with metastatic colorectal cancer: Interim results of the noninterventional CASSIOPEE study. *J Clin Oncol*, 2016, ASCO Annual Meeting, dopl. 2016, abstrakt 3555.
- 7 Hirt, S. – Borg, Ch. – Bertaut, A., et al.: Bevacizumab or cetuximab plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wtKRAS metastatic colorectal cancer: A randomized phase II study (Prodige 18 – UNICANCER GI). *J Clin Oncol*, 2016, ASCO Annual Meeting, dopl., abstrakt 3514.
- 8 Nixon, A. B.: Blood-based biomarkers in patients (pts) with metastatic colorectal cancer (mCRC) treated with FOLFOX or FOLFIRI plus bevacizumab (Bev), cetuximab (Cetux), or bev plus Cetux: Results from CALGB 80405 (Alliance). *ASCO 2016*, abstrakt 3597, doi: <http://meetinglibrary.asco.org/content/1236607?media=vm&poster=1>.

# Pokroky v systémové léčbě karcinomu děložního hrdla

MUDr. Igor Sirák, Ph.D. Klinika onkologie a radioterapie FN, Hradec Králové

- 1 Bloss, J. D. – Blessing, J. A. – Behrens, B. C., et al.: Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a Gynecologic Oncology Group study. *J Clin Oncol*, 2002, 20, s. 1832–1837.
- 2 Bonomi, P. – Blessing, J. A. – DiSaia, P. J., et al.: Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology study. *J Clin Oncol*, 1985, 3, s. 1079–1085.
- 3 Bray, F. – Ren, J. S. – Masuyer, E., et al.: Global estimates of cancer prevalence for 27 sites in the adult population in 2008. *Int J Cancer*, 2013, 132, s. 1133–1145, doi: 10.1002/ijc.27711.
- 4 Brewer, C. A. – Blessing, J. A. – Nagourney, R. A., et al.: Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix. *Gynecol Oncol*, 2006, 100, s. 385–388.
- 5 Ferlay, J. – Parkin, D. M. – Steliarova-Foucher, E.: Estimates of cancer incidence and mortality in Europe in 2008. *Eur J Cancer*, 2010, 46, s. 765–781, doi: 10.1016/j.ejca.2009.12.014.
- 6 Forman, D. – de Martel, C. – Lacey, C. L., et al.: Global burden of human papillomavirus and related diseases. *Vaccine*, 2012, 30, s. F12–23.
- 7 Kitagawa, R. – Katsumata, N. – Shibata, T., et al.: A randomized, phase III trial of paclitaxel plus carboplatin (TC) versus paclitaxel plus cisplatin (TP) in stage IVb, persistent or recurrent cervical cancer: Japan Clinical Oncology Group study (JCOG0505) [abstrakt]. *J Clin Oncol*, 2012, 30, abstrakt 5006.
- 8 Long, H. J. 3<sup>rd</sup>. – Bundy, B. N. – Grendys, E. C. Jr., et al.: Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. *J Clin Oncol*, 2005, 23, s. 4626–4633.
- 9 Monk, B. J. – Sill, M. W. – McMeekin, D. S., et al.: Phase III trial of four cisplatin-containing doublet combinations in stage IVb, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group Study. *J Clin Oncol*, 2009, 27, s. 4649–4655.
- 10 Moore, D. H. – Blessing, J. A. – McQuellon, R. P., et al.: Phase III study of cisplatin with or without paclitaxel in stage IVb, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. *J Clin Oncol*, 2004, 22, s. 3113–3119.
- 11 Moore, K. N. – Herzog, T. J. – Lewin, S., et al.: A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVb, recurrent or persistent cervical cancer. *Gynecol Oncol*, 2007, 105, s. 299–303.
- 12 Omura, G. A. – Blessing, J. A. – Vaccarello, L., et al.: Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. *J Clin Oncol*, 1997, 17, s. 165–171.
- 13 Tewari, K. S. – Sill, M. W. – Long, H. J., et al.: Improved survival with bevacizumab in advanced cervical cancer. *N Engl J Med*, 2014, 370, s. 734–743.
- 14 Thigpen, J. T. – Blessing, J. A. – DiSaia, P. J., et al.: A randomized comparison of a rapid versus prolonged (24 hr) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study. *Gynecol Oncol*, 1989, 32, s. 198–202.
- 15 Thigpen, T.: The role of chemotherapy in the management of carcinoma of the cervix. *Cancer J*, 2003, 9, s. 425–432.
- 16 GLOBOCAN 2012. *Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012*. International Agency for Research on Cancer. World Health Organization, dostupné z: <http://globocan.iarc.fr/Default.aspx>, vyhledáno 13. 6. 2016.

## Proč k fentanylovým náplastem přidávat i Effentoru?

MUDr. Josef Kvěch Radioterapeuticko-onkologické oddělení FN Motol, Praha

- 1 Vyzula, R., et al.: Modrá kniha České onkologické společnosti ČLS JEP, 22. aktualizace, Masarykův onkologický ústav, 2016. Ke stažení: <http://www.linkos.cz/files/modra-kniha/15.pdf>.

## Nádory gastrointestinálního traktu, dopad na nutriční stav pacientů a možnosti nutriční podpory

MUDr. Petra Holečková, Ph.D., MBA

Ústav radiační onkologie, Nemocnice Na Bulovce a 1. LF UK, Praha

- 1 Fearon, K., et al.: Definition and classification of cancer cachexia: an international consensus. *Lancet Oncol*, 2011, 12, s. 489–495.
- 2 Muscaritoli, M. – Anker, S. D. – Argilés, J.: Consensus definitiv of sarcopenia, cachexia and precachexia: Joint dokument elaborated by Special Interest Groups (SIG) „cachexia – anorexia in chronic casting diseases“ and, „nutrition in geriatrics“. *Clinical Nutrition*, 2010, 29, s. 154–159.
- 3 Holečková, P. – Novotný, J.: Výživa onkologicky nemocných. In: Novotný, J. – Vítek, P., et al.: *Onkologie v klinické praxi*. Mladá Fronta, 2012, s. 512–522.
- 4 Thoresen, L. – Frykholm, G. – Lydersen, S., et al.: Nutritional status, cachexia and survival in patients with advanced colorectal carcinoma. Different assessment criteria for nutritional status provide unequal results. *Clinical Nutrition*, 2013, 32, s. 65–72.
- 5 Martin, L. – Senesse, P. – Gioulbasanis, I., et al.: Diagnostic criteria for the classification of cancer-associated weight loss. *Clin Oncol*, 2015, 33, s. 90–99.
- 6 Barret, M. – Dalban, C. – Taieb, J., et al.: Effect of cancer cachexia on treatment toxicity in metastatic colorectal cancer patients: Results of a prospective multicenter study. *J Clin Oncol*, 2012, 30, dopl. 9026.
- 7 Manasek, V. – Bezdek, K. – Foltys, A., et al.: Effect of early nutrition with protein ONS on complications of the patients with colorectal cancer. European Cancer Congress 2013 (ECCO 17<sup>th</sup>, ESMO 38<sup>th</sup>), 29. 9. 2013.
- 8 Gardner, J. R. – Livingston, P. M. – Fraser, S. F.: Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review. *J Clin Oncol*, 2014, 32, s. 335–346.
- 9 Holečková, P. – Beneš, P. – Deus, M. – Štěpánek, L.: *Význam individualizované nutriční péče v onkologické ambulanci*. Grant AVKV, XXXI. Mezinárodní kongres SKVIMP a 1. česko-slovenský kongres klinické výživy, 7. 3. 2015, Hradec Králové.
- 10 Di Girolamo, F. G. – Sitalin, R. – Mazzucco, S., et al.: Omega-3 fatty acids and protein metabolism: enhancement of anabolic interventions for sarcopenia. *Curr Opin Clin Nutr Metab Care*, 2014, 17, s. 145–150.
- 11 Tomiška, M. – Novotná, Š. – Kováčková, L., et al.: Vitamin D při léčbě nádorového onemocnění. *Klin Onkol*, 2015, 28, s. 99–104.
- 12 Hoskovec, D.: Karcinom žaludku. *Onkologie*, 2015, 9, s. 272–276.
- 13 Dostupné z: <http://www.linkos.cz/pracovni-skupina-nutricni-pece-v-onkologii-pri-cos/materialy-pro-praxi-ke-stazeni/vyhledano> 6. 9. 2016.
- 14 Mercadante, S.: Parenteral versus enteral nutrition in cancer patient: indications and practice. *Support Care Cancer*, 1998, 2, s. 85.
- 15 Beneš, P.: Role parentální výživy v podpůrné onkologické léčbě – nový pohled. *ACTA MEDICINAE*, 2014, 8, s. 67–71.
- 16 Tomiška, M.: Nutriční podpora formou sippingu. *Praktické lékárenství*, 2009, 5, s. 10–11.
- 17 Stratton, R. – Elia, M.: A review of reviews a new look at the evidence for oral nutritional supplements in clinical practice. *Clin Nutr Suppl*, 2007, 2, s. 5–23.
- 18 Hindy, P. – Hong, J. – Lam-Tsai, Y., et al.: A comprehensive review of esophageal stents. *Gastroenterol Hepatol*, 2012, 8, s. 526–534.
- 19 Maňásek, V. – Bezdek, K.: Perioperative oral nutrition support in colorectal patient may improve clinical and health economics outcomes. *Ann Oncol*, 2015, 26, dopl. 4.

## Imunoglobuliny v sekundární imunodeficienci

MUDr. Mgr. Jitka Petanová, CSc. Ústav imunologie a mikrobiologie, 1. LF UK a VFN, Praha

- 1 Dorsey, M. J. – Ho, V. – Mabudian, M., et al.: Clinical experience with an L-proline-stabilized 10% intravenous immunoglobulin (Privigen): Real-life effectiveness and tolerability. *J Clin Immunol*, 2014, 34, s. 804–812.
- 2 Králíčková, P.: Současné formy imunoglobulinové substituční léčby. *Alergie*, 2016, 2, s. 129–132.
- 3 Matucci, A. – Maggi, E. – Vultaggio, A.: Mechanisms of action of Ig preparations: immunomodulatory and anti-inflammatory effects. *Front Immunol*, 2015, 5, s. 690, <http://journal.frontiersin.org/article/10.3389/fimmu.2014.00690>.
- 4 Seppänen, M.: Immunoglobulin G treatment of secondary immunodeficiencies in the era of novel therapies. *Clin Exp Immunol*, 2014, 178, s. 10–13.
- 5 Windegger, T. M., et al.: Subcutaneous immunoglobulin therapy for hypogammaglobulinemia secondary to malignancy or related drug therapy. *Transfus Med Rev*, 2016, <http://dx.doi.org/10.1016/j.tmr.2016.06.006>.
- 6 SPC humánních imunoglobulinů určených pro intravenózní, subkutánní a intramuskulární aplikaci.